GENUS ONCOLOGY - THE MUC1-C COMPANY
  • Company
    • Mission
    • About Us
    • Genus Overview
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Clinical and Research Partners
    • Contact
    • Sitemap
  • Why Target MUC1-C?
  • Clinical Trials
    • Summary
    • GO-203
    • Phase 2 AML Clinical Trial
  • The Science
    • Overview
    • MUC1 in Human Cancer: The Numbers
    • MUC1 in Human Cancer: Overexpression
    • Target for Carcinoma Stem-Like Cell
    • Target for Leukemia Stem Cell
    • MUC1-C is an Attractive Target for Reversing Immune Evasion
    • Intellectual Property
  • Programs
    • Pipeline
    • Targeting the Cytoplasmic Domain
    • Targeting the Extracellular Domain
    • Biomarker Program
  • News & Publications
    • News
    • Publications >
      • Complete Listing
      • Role of MUC1-C in Signal Transduction
      • Role of MUC1-C in Epigenetic Regulation
      • Role of MUC1-C in Immune Evasion
      • MUC1 Vaccine
      • MUC1-C in Stem-like Cells
      • MUC1-C inhibitor formulated in Nanoparticles
      • MUC1-C inhibitor is synergistic with chemotherapeutic and targeted drugs
      • MUC1-C is a druggable target

Why Target MUC1-C?

Normal Cells

MUC1-N Physically Protects Cell Surface
Picture
MUC1-C is Activated in Response to Inflammation and Other Forms of Stress
MUC1 Overexpressed in ~900,000 Tumors Diagnosed Each Year in the US
Breast, NSCLC, Prostate, Ovarian, Pancreatic, Colon and Hematologic Malignancies

MUC1 Expression Increased 50-100x In Cancer Cells

MUC1 is Expressed in Solid Tumor and Leukemia Stem-like Cells

Targeting MUC1-C Overcomes Drug Resistance

Inhibition of MUC1-C Synergizes with Chemotherapeutics and Targeted Agents 

MUC1 Blocks Immune Recognition and Destruction

Cancer Cells

MUC1-N is shed from the tumor cell surface
Picture
MUC1-C Induces Proliferation

​MUC1-C Blocks Cell Death

Picture

Genus Oncology is Developing Multiple Approaches to Target the Non-Shed MUC1-C Subunit

​Early attempts at targeting MUC1, particularly with antibodies, focused on MUC1-N and were ineffective because this subunit is shed from the cancer cell surface.
Genus Programs Targeting the
​MUC1-C Cytoplastic Domain
  • GO-203 Phase 1b/2a in AML (Harvard)
  • GO-203 Nanoparticles (NPs)
Picture
Genus Programs Targeting the
​MUC1-C Extracellular Domain
  • ADC: Antibody-drug conjugate
  • ADCC: Antibody-dependent cell-mediated cytotoxicity
  • BsAb: Bispecific
  • CAR-T

Company

About Us
Management
Board of Directors
​Contact
​
Sitemap

Science

MUC1-C
Why Target?
MUC1-C in Stem Cells
Publications

Programs

Targeting
Biomarker
Intellectual Property

Pipeline

Pipeline
​Clinical Trials

News

News
​Publications
© COPYRIGHT 2019 ALL RIGHTS RESERVED.
  • Company
    • Mission
    • About Us
    • Genus Overview
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Clinical and Research Partners
    • Contact
    • Sitemap
  • Why Target MUC1-C?
  • Clinical Trials
    • Summary
    • GO-203
    • Phase 2 AML Clinical Trial
  • The Science
    • Overview
    • MUC1 in Human Cancer: The Numbers
    • MUC1 in Human Cancer: Overexpression
    • Target for Carcinoma Stem-Like Cell
    • Target for Leukemia Stem Cell
    • MUC1-C is an Attractive Target for Reversing Immune Evasion
    • Intellectual Property
  • Programs
    • Pipeline
    • Targeting the Cytoplasmic Domain
    • Targeting the Extracellular Domain
    • Biomarker Program
  • News & Publications
    • News
    • Publications >
      • Complete Listing
      • Role of MUC1-C in Signal Transduction
      • Role of MUC1-C in Epigenetic Regulation
      • Role of MUC1-C in Immune Evasion
      • MUC1 Vaccine
      • MUC1-C in Stem-like Cells
      • MUC1-C inhibitor formulated in Nanoparticles
      • MUC1-C inhibitor is synergistic with chemotherapeutic and targeted drugs
      • MUC1-C is a druggable target